Company Profile
Mirum Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- MIRM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
79.25 USD (-2.68%)
Close
Last updated: October 6, 2026
5.62B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, MIRM closed down 2.68% at $79.25. No new same-company headline was identified in the current news window.
Company overview
Rare Liver Disease Company
Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases, with particular expertise in disorders involving bile-acid dysregulation and severe cholestatic pruritus. Its model combines a global specialty commercial organization with late-stage internal development programs.
LIVMARLI Cholestatic Disease Franchise
LIVMARLI, an ileal bile acid transporter inhibitor, is marketed for cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis. The product anchors Mirum's commercial presence in pediatric and genetically defined liver diseases.
Established Bile-Acid Medicines
Mirum also markets bile-acid therapies for rare metabolic liver conditions, broadening its revenue base and relationships with hepatology centers. These products complement LIVMARLI and support a focused infrastructure for small patient populations requiring specialist diagnosis and long-term treatment.
Late-Stage Hepatology Pipeline
Volixibat is being developed for cholestatic pruritus in primary sclerosing cholangitis and primary biliary cholangitis. Brelovitug targets chronic hepatitis delta, while LIVMARLI lifecycle studies seek to extend the company's lead franchise into additional cholestatic settings.
Pipeline Beyond Liver Disease
Zilurgisertib is an ALK2 inhibitor for fibrodysplasia ossificans progressiva, and MRM-3379 is a PDE4D program for Fragile X syndrome. These assets expand Mirum into rare skeletal and neurodevelopmental diseases while preserving a specialty-pharma operating model.
Future catalysts
- FDA PDUFA decision for zilurgisertib in fibrodysplasia ossificans progressiva on September 26, 2026.
- AZURE-1 data for brelovitug in chronic hepatitis delta in the third quarter of 2026 and AZURE-4 data in the fourth quarter of 2026.
- Phase 3 EXPAND results for LIVMARLI in the fourth quarter of 2026.
- Phase 2b VANTAGE results for volixibat in primary sclerosing cholangitis in the first quarter of 2027.
- Potential volixibat NDA submission in primary sclerosing cholangitis in the first half of 2027, subject to FDA discussions.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
Mirum Pharmaceuticals (MIRM) most recently closed at 79.25 USD, a -2.68% move versus the previous session.
What is the market cap of Mirum Pharmaceuticals (MIRM)?
Mirum Pharmaceuticals currently has a market capitalization of 5.62B USD on BioPharmSignal.
What does Mirum Pharmaceuticals do?
Rare Liver Disease Company Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases, with particular expertise in disorders involving bile-acid dysregulation and severe cholestatic pruritus. Its model combines a global specialty commercial organization with late-stage internal development programs. LIVMARLI Cholestatic Disease...
On which exchange is MIRM stock listed?
Mirum Pharmaceuticals (MIRM) is associated with NASDAQ, United States, Biopharma.
What is MRM-3379?
Pipeline Beyond Liver Disease Zilurgisertib is an ALK2 inhibitor for fibrodysplasia ossificans progressiva, and MRM-3379 is a PDE4D program for Fragile X syndrome.
Which conditions is Mirum Pharmaceuticals targeting with MRM-3379?
Mirum Pharmaceuticals is associated with metabolic disease, genetic disease based on its company overview and current catalyst commentary.
How does Mirum Pharmaceuticals describe recent progress with MRM-3379?
FDA PDUFA decision for zilurgisertib in fibrodysplasia ossificans progressiva on September 26, 2026. AZURE-1 data for brelovitug in chronic hepatitis delta in the third quarter of 2026 and AZURE-4 data in the fourth quarter of 2026. Phase 3 EXPAND results for LIVMARLI in the fourth quarter of 2026. Phase 2b VANTAGE results for volixibat in primary...
What is AZURE-1?
AZURE-1 data for brelovitug in chronic hepatitis delta in the third quarter of 2026 and AZURE-4 data in the fourth quarter of 2026.